H.I.G. Capital-backed Surgery Partners unveils IPO

Surgery Partners, a portfolio company of H.I.G. Capital, has rolled out its IPO after pricing its 14.29 million shares at $19 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “SGRY.” BofA Merrill Lynch, Goldman Sachs and Jefferies LLC are serving as lead underwriters. Surgery Partners is surgical services provider. PRESS RELEASE NASHVILLE, Tenn., Sept. 30, 2015 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (the “Company”), a leading healthcare services company, today announced the pricing of its initial public offering (“IPO”) of 14,285,000 shares of common stock at a public offering price of $19.00 per share. The underwriters have also been granted an option to purchase up to 2,142,750 secondary shares from certain of the Company’s stockholders at the public offering price less underwriting discounts and commissions. The Company’s common stock is expected to begin trading on the NASDAQ Global Market under the ticker symbol “SGRY” on October 1, 2015. The offering is expected to close on October 6, 2015, subject to customary closing conditions. BofA Merrill Lynch, Goldman, Sachs & Co. and Jefferies LLC will be acting as joint book-running managers and representatives of the underwriters for the offering. Citigroup, Morgan Stanley, Credit Suisse Securities (USA) LLC, Raymond James & Associates, Inc. and RBC Capital Markets will be acting as joint book-runners, and Stifel will be acting as co-manager. A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on September 30, 2015. The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering will be filed with the SEC and copies may be obtained, when available, by contacting (i) BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or by email at dg.prospectus_requests@baml.com, (ii) Goldman, Sachs & Co., 200 West Street, New York, NY 10282, Attn: Prospectus Department, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com, or (iii) Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Surgery Partners Surgery Partners is a leading healthcare services company with a differentiated outpatient delivery model focused on providing high quality, cost effective solutions for surgical and related ancillary care in support of both patients and physicians. Founded in 2004, Surgery Partners is one of the largest and fastest growing surgical services businesses in the country, with a portfolio of 99 surgical facilities comprised of 94 ambulatory surgery centers and 5 surgical hospitals across 28 states.

See the article here:
H.I.G. Capital-backed Surgery Partners unveils IPO

VC-backed Edge Therapeutics goes public

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has debuted its IPO after pricing its over 7.3 million shares at $11 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “EDGE.” Leerink Partners and Credit Suisse are serving as the lead underwriters. Edge Therapeutics’ backers included Venrock, Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. PRESS RELEASE Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced the pricing of its initial public offering of 7,315,151 shares of its common stock at a public offering price of $11.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Edge Therapeutics. In addition, Edge Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1,097,272 shares of common stock at the same price, to cover over-allotments, if any. The shares are scheduled to begin trading on The NASDAQ Global Select Market on October 1, 2015 under the ticker symbol “EDGE.” Leerink Partners and Credit Suisse are acting as joint book-running managers for the offering. Guggenheim Securities and JMP Securities are acting as co-managers. The offering is being made only by means of a prospectus. A copy of the final prospectus related to this offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at syndicate@leerink.com, or by phone at (800) 808-7525, ext. 6124, or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by telephone at (800) 221-1037, or by email at newyork.prospectus@credit-suisse.com. A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on September 30, 2015. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction. About Edge Therapeutics Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment in the management of chronic subdural hematoma, to prevent recurrent bleeding on the surface of the brain. For additional information about Edge Therapeutics, please visit www.edgetherapeutics.com.

Read more here:
VC-backed Edge Therapeutics goes public

PE-backed CPI Card Group sets IPO pricing terms

Littleton, Colorado-based CPI Card Group, a provider of financial, commercial and ID cards, has priced its IPO of over 17.6 million shares at between $16 and $18 per share. BMO Capital Markets, Goldman Sachs and CIBC are serving as the lead underwriters. CPI Card Group is backed by Tricor Pacific Capital. PRESS RELEASE LITTLETON, COLORADO, Sep 22, 2015 (Marketwired via COMTEX) — CPI Card Group Inc. (the “Company”) today announced that it has commenced an underwritten initial public offering of 17,647,059 shares of common stock with 8,982,353 shares to be sold by the Company and 8,664,706 shares to be sold by certain existing stockholders (the “Selling Stockholders”). The initial public offering price is expected to be between US$16.00 and US$18.00 per share of common stock. The underwriters will have a 30-day option to purchase up to an additional 2,647,059 shares of common stock from the Selling Stockholders. The Company expects to receive net proceeds of approximately US$140 million from the offering and intends to use such proceeds to redeem the remaining outstanding shares of its preferred stock, to terminate its phantom stock plan and to satisfy all liabilities due thereunder and to repay outstanding indebtedness. BMO Capital Markets, Goldman, Sachs & Co. and CIBC will act as joint book-running managers for the offering. A registration statement, on Form S-1 relating to these securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. A preliminary prospectus relating to these securities has also been filed with the securities regulatory authorities in each of the provinces and territories of Canada. The preliminary prospectus is subject to completion or amendment. There will not be any sale or any acceptance of any offers to buy these securities in any province or territory of Canada until a receipt for a final prospectus has been obtained from the securities regulatory authorities in such provinces and territories. Copies of the Canadian preliminary prospectus may be obtained from the underwriters at the addresses set out below and is available on SEDAR at www.sedar.com. The offering of these securities will be made only by means of a prospectus. A copy of the U.S. preliminary prospectus related to the offering has been filed with the SEC and may be obtained from: BMO Capital Markets Corp., Attn: Equity Syndicate Department, 3 Times Square, New York, NY 10036, or by telephone at 1-(800)-414-3627 or by email at bmoprospectus@bmo.com; Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at 1-(866)-471-2526 or by email at prospectus-ny@ny.email.gs.com; or CIBC, by telephone at 1-(800)-282-0822 or by email at useprospectus@us.cibc.com. This press release does not constitute an offer to sell or a solicitation of an offer to buy the Company’s common stock, nor shall there be any sale of such shares in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Follow this link:
PE-backed CPI Card Group sets IPO pricing terms